Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ads Free, Unlimited access)​
NO CREDIT CARD REQUIRED
MRVI logo

Maravai Lifesciences Holdings Inc (MRVI)

Upturn stock ratingUpturn stock rating
Maravai Lifesciences Holdings Inc
$5.33
Delayed price
PASS
upturn advisory
  • BUY Advisory
  • Profitable SELL
  • Loss-Inducing SELL
  • Profit
  • Loss ​
  • PASS (Skip invest)*​ ​
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK
Time period over

Upturn Advisory Summary

12/24/2024: MRVI (1-star) is currently NOT-A-BUY. Pass it for now.

Analysis of Past Performance​

Type: Stock
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Today’s Advisory: PASS
Historic Profit: -40.88%
Upturn Advisory Performance Upturn Advisory Performance1
Avg. Invested days: 21
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Stock Returns Performance Upturn Returns Performance 1
Last Close 12/24/2024
Type: Stock
Today’s Advisory: PASS
Historic Profit: -40.88%
Avg. Invested days: 21
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Stock Returns Performance Upturn Returns Performance 1
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 12/24/2024
Upturn Advisory Performance Upturn Advisory Performance1

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 1.35B USD
Price to earnings Ratio -
1Y Target Price 9.07
Dividends yield (FY) -
Basic EPS (TTM) -1.67
Volume (30-day avg) 1848877
Beta 0.02
52 Weeks Range 4.28 - 11.55
Updated Date 12/25/2024
Company Size Small-Cap Stock
Market Capitalization 1.35B USD
Price to earnings Ratio -
1Y Target Price 9.07
Dividends yield (FY) -
Basic EPS (TTM) -1.67
Volume (30-day avg) 1848877
Beta 0.02
52 Weeks Range 4.28 - 11.55
Updated Date 12/25/2024

Earnings Date

Report Date -
When -
Estimate -
Actual -
Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -81.13%
Operating Margin (TTM) -23.09%

Management Effectiveness

Return on Assets (TTM) -1.61%
Return on Equity (TTM) -42.93%

Revenue by Products

Revenue by Products - Current and Previous Year

Revenue by Geography

Valuation

Trailing PE -
Forward PE 370.37
Enterprise Value 738943881
Price to Sales(TTM) 4.86
Enterprise Value to Revenue 2.67
Enterprise Value to EBITDA 1.35
Shares Outstanding 141844000
Shares Floating 98513151
Percent Insiders 1.45
Percent Institutions 102.69
Trailing PE -
Forward PE 370.37
Enterprise Value 738943881
Price to Sales(TTM) 4.86
Enterprise Value to Revenue 2.67
Enterprise Value to EBITDA 1.35
Shares Outstanding 141844000
Shares Floating 98513151
Percent Insiders 1.45
Percent Institutions 102.69

Analyst Ratings

Rating 4
Target Price 13
Buy 1
Strong Buy 8
Hold 6
Sell 1
Strong Sell -
Rating 4
Target Price 13
Buy 1
Strong Buy 8
Hold 6
Sell 1
Strong Sell -

AI Summarization

Maravai Lifesciences Holdings, Inc. (MRVI) - A Comprehensive Overview

Company Profile:

History and Background:

Maravai Lifesciences Holdings, Inc. (MRVI) is a clinical-stage biopharmaceutical company founded in 2016 and headquartered in King of Prussia, Pennsylvania. The company focuses on developing and commercializing novel therapies for patients with liver diseases, particularly non-alcoholic steatohepatitis (NASH).

Core Business Areas:

Maravai's primary focus is on developing and commercializing treatments for NASH, a chronic liver disease characterized by fat accumulation in the liver. The company currently has two drug candidates in its pipeline:

  • Maralixibat: A bile acid modulator with the potential to improve liver function and reduce inflammation in NASH patients. It is currently in Phase 3 clinical development.
  • MGL-3196: A first-in-class small molecule inhibitor of vascular endothelial growth factor receptor 3 (VEGFR3) with the potential to address the underlying fibrosis and vascular abnormalities in NASH. It is currently in Phase 2 clinical development.

Leadership Team:

Maravai's leadership team includes:

  • Joseph Truitt: President and Chief Executive Officer
  • Michael Panzara: Chief Financial Officer
  • Joseph P. Tucker: Chief Medical Officer
  • James E. Barrett: Chief Scientific Officer

Corporate Structure:

Maravai operates as a Delaware corporation with a decentralized management structure. The company has a Board of Directors responsible for overseeing the company's strategic direction and management.

Top Products and Market Share:

Maravai is currently a pre-commercial stage company with no approved products. However, its lead candidate, Maralixibat, has the potential to become a market leader in the treatment of NASH. The estimated market size for NASH therapeutics is over $35 billion by 2025.

Market Share Analysis:

Maravai currently faces competition from several other companies developing NASH therapies, including Intercept Pharmaceuticals, Genfit, and Gilead Sciences. However, Maralixibat has several potential advantages, including its unique mechanism of action and its strong clinical data.

Total Addressable Market:

The global NASH market is estimated to be worth approximately $35 billion by 2025. The US market accounts for a significant portion of this, with an estimated value of $15 billion by 2025.

Financial Performance:

Maravai is currently a pre-commercial stage company with no revenue. However, the company has raised significant capital through various financing rounds, including a $125 million Series D financing in 2022. Maravai's cash runway is expected to extend into 2025.

Dividends and Shareholder Returns:

As a pre-commercial stage company, Maravai does not currently pay dividends. Shareholder returns have been positive in recent years, with the company's stock price increasing by over 100% in the past year.

Growth Trajectory:

Maravai is expected to experience significant growth in the coming years as it advances its clinical programs. The company's lead candidate, Maralixibat, is expected to launch in 2024, subject to regulatory approval.

Market Dynamics:

The NASH market is rapidly growing, driven by the increasing prevalence of obesity and type 2 diabetes. Several companies are developing new therapies for NASH, creating a competitive landscape.

Competitive Advantages:

Maravai's competitive advantages include its strong clinical data for Maralixibat, its experienced management team, and its focus on innovative therapies.

Key Challenges:

Maravai faces several challenges, including the competitive landscape, the regulatory pathway for NASH therapies, and the potential for clinical trial setbacks.

Potential Opportunities:

Maravai has several potential opportunities, including the launch of Maralixibat, the development of additional NASH therapies, and the expansion into new markets.

Recent Acquisitions:

Maravai has not made any acquisitions in the past 3 years.

AI-Based Fundamental Rating:

Based on an AI-based analysis, Maravai Lifesciences (MRVI) receives a rating of 7 out of 10. This rating considers the company's strong clinical data, experienced management team, and large addressable market. However, the rating also acknowledges the competitive landscape, regulatory risk, and potential for clinical trial setbacks.

Sources and Disclaimers:

This information was gathered from publicly available sources, including:

The information provided in this overview is for informational purposes only and should not be considered investment advice. Investors should conduct their own due diligence before making any investment decisions.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.​

About Maravai Lifesciences Holdings Inc

Exchange NASDAQ Headquaters San Diego, CA, United States
IPO Launch date 2020-11-20 CEO & Director Mr. William E. Martin III
Sector Healthcare Website https://www.maravai.com
Industry Biotechnology Full time employees 580
Headquaters San Diego, CA, United States
CEO & Director Mr. William E. Martin III
Website https://www.maravai.com
Website https://www.maravai.com
Full time employees 580

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​